LENSAR Q2 Revenue Beats by 13%, Swings to Profit on ALLY Demand
LNSR sits 50% above its 52-week low of $4.95.
Summary
LENSAR reported Q2 revenue of $16.5 million, up 18% year-over-year and beating the $14.65 million consensus by 13%. The company swung to a net profit of $3.5 million, or $0.10 per share, driven by 23% growth in procedure revenue and a $1.1 million tariff refund. Recurring revenue rose 20%, and ALLY system placements and backlog increased, indicating sustained demand. This follows the 8-K filed earlier today and provides analyst consensus context. No forward guidance was given, but the strong beat and return to profitability are likely to support the stock's recent momentum.
At the time of this announcement, LNSR was trading at $7.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.1M. The 52-week trading range was $4.95 to $13.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.